Significance of regular somatostatin analogues and interferon-alfa application in patients with highly differentiated neuroendocrine tumors (clinical case)
Open Access
- 15 December 2014
- journal article
- Published by ECO-Vector LLC in Russian Journal of Oncology
- Vol. 19 (6) , 30-32
Abstract
Presented clinical case demonstrates the importance of regular use of somatostatin analogues and interferon-alpha in patients with well differentiated NETs.Keywords
This publication has 10 references indexed in Scilit:
- Interferon Therapy of Malignant Endocrine Pancreatic Tumors12015
- Rationale for the use of somatostatin analogs as antitumor agentsAnnals of Oncology, 2006
- Octreotide Versus Octreotide Plus Interferon-Alpha in Endocrine Gastroenteropancreatic Tumors: A Randomized TrialClinical Gastroenterology and Hepatology, 2005
- Interferon-α: Regulatory Effects on Cell Cycle and AngiogenesisNeuroendocrinology, 2004
- The Diagnosis and Medical Management of Advanced Neuroendocrine TumorsEndocrine Reviews, 2004
- Prospective, Randomized, Multicenter Trial on the Antiproliferative Effect of Lanreotide, Interferon Alfa, and Their Combination for Therapy of Metastatic Neuroendocrine Gastroenteropancreatic Tumors—The International Lanreotide and Interferon Alfa Study GroupJournal of Clinical Oncology, 2003
- Randomized clinical trial of the effect of interferon α on survival in patients with disseminated midgut carcinoid tumoursBritish Journal of Surgery, 2003
- Interferon in the Management of Neuroendocrine GEP-TumorsDigestion, 2000
- Molecular Biology of Somatostatin Receptors*Endocrine Reviews, 1995
- Natural killer cell activity in patients with neuroendocrine tumours of the gastrointestinal tract; Relation with circulating gastrointestinal hormonesNeuropeptides, 1991